Controlled Ovarian Stimulation

Injectable gonadotropins supply follicle-stimulating hormone and, when included, luteinizing hormone activity to support coordinated follicular development. Rather than relying on the growth of a single follicle, treatment promotes several follicles that may yield mature oocytes. This broader follicular response is important when a procedure needs more than one egg for collection, laboratory use, or preservation.

GnRH agonists or antagonists are used to suppress the risk of a premature luteinizing hormone surge during follicular development. Preventing an unexpectedly early hormonal transition helps clinicians retain control over the timing of final oocyte maturation and the planned procedure. Their role is regulatory: they coordinate treatment timing rather than directly supplying the main follicle-growth stimulus.

Ultrasound shows how follicles are developing, while hormone measurements provide complementary information about the ovarian response. Clinicians use these findings to adjust medication doses and decide when maturation should be triggered. Monitoring also helps identify an excessive or inadequate response early, supporting safer treatment planning and reducing the chance that timing or dosing will be based on medication alone.

After follicles have developed, a trigger is given to promote final oocyte maturation. Its timing links the biological state of the follicles to the next clinical step, such as egg collection in an in vitro fertilization or oocyte-cryopreservation cycle, or coordinated ovulation in selected assisted-insemination protocols. The trigger therefore converts monitored follicular development into a scheduled treatment event.

Controlled ovarian stimulation is selected when clinicians need coordinated access to one or more mature eggs or controlled ovulation for a fertility procedure. In vitro fertilization and oocyte cryopreservation generally use it to support egg collection, whereas some assisted insemination protocols use it to coordinate ovulation. The application depends on whether eggs will be collected, preserved, or used for insemination.

Treatment response is managed through ongoing assessment rather than a fixed medication schedule. Ultrasound and hormone monitoring show whether follicular growth is progressing as intended, allowing dose adjustments and informing the timing of the trigger. This individualized approach is especially relevant because ovarian hyperstimulation is a potential complication; monitoring helps clinicians recognize response patterns that require careful management.